Skip to NavigationSkip to content

Novartis pulls fevipiprant development in asthma following trial failure

Published on 16/12/19 at 12:48pm

Novartis has made it known that its DP2 receptor antagonist fevipiprant failed at Phase 3 to show clinically relevant levels of efficacy in the treatment of inadequately controlled moderate-to-severe asthma.

The firm announced that neither the 150mg or 450mg therapy formulations reached the “clinically relevant threshold” in reducing the moderate-to-severe exacerbation rate over 52 weeks in asthma patients who had received inhaled mid-to-high dose corticosteroids (ICS) and at least one additional controller, compared to placebo.

Novartis said that the data “do not support further development of fevipiprant in asthma”.

However, Novartis’ noted that the therapy was “generally well-tolerated”. Full efficacy and safety data was confirmed to be under analysis and will be presented at an upcoming medical meeting.

“While the results of the LUSTER studies with fevipiprant are disappointing, they meaningfully contribute to our understanding of the DP2 pathway in asthma. We are incredibly grateful to all the patients, their families and the investigators who participated in the studies and contributed greatly to this research,” remarked John Tsai, Head Global Drug Development and Chief Medical Officer at Novartis.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches